menu ☰
menu ˟

FDA grants orphan drug designation to CLR 131 for Ewing sarcoma

10 Jul 2018
The FDA granted orphan drug designation to CLR 131 for treatment of Ewing sarcoma, according to the agent’s manufacturer.CLR 131 (Cellectar Biosciences) is an investigational radioiodinated phospholipid drug conjugate therapy designed to exploit th...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.